What do systematic reviews say?

MgSO4 vs placebo

MgSO4 may leads to lower hospital admissions compared with placebo (low certainty).

• Intravenous magnesium sulfate for treating children with acute asthma in the emergency department 2016 · Cochrane Headline outcomes only
  OR 0.32 [0.14, 0.74]
  3 studies · 115 participants
  Low

MgSO4 vs placebo

• Intravenous magnesium sulfate for treating children with acute asthma in the emergency department 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Low

MgSO4 vs placebo

MgSO4 showed no clear difference in return to ED within 48 hours compared with placebo (low certainty).

• Intravenous magnesium sulfate for treating children with acute asthma in the emergency department 2016 · Cochrane Headline outcomes only
  OR 0.4 [0.02, 10.3]
  2 studies · 85 participants
  Low

MgSO4 vs placebo

• Intravenous magnesium sulfate for treating children with acute asthma in the emergency department 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 47 participants
  Low

Intervention not reported

The intervention showed no clear difference in mortality during hospitalisation number of infants with event (moderate certainty).

• Intravenous in‐line filters for preventing morbidity and mortality in neonates 2015 · Cochrane Headline outcomes only
  RR 0.87 [0.52, 1.47]
  2 studies · 530 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in risk of proven septicaemia per infant number of infants with the event (moderate certainty).

• Intravenous in‐line filters for preventing morbidity and mortality in neonates 2015 · Cochrane Headline outcomes only
  RR 0.86 [0.59, 1.27]
  2 studies · 530 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in suspected septicaemia number of infants with the event (low certainty).

• Intravenous in‐line filters for preventing morbidity and mortality in neonates 2015 · Cochrane Headline outcomes only
  RR 0.57 [0.18, 1.81]
  1 study · 88 participants
  Low

Intervention not reported

The intervention showed no clear difference in localised thrombi number of infants with event (low certainty).

• Intravenous in‐line filters for preventing morbidity and mortality in neonates 2015 · Cochrane Headline outcomes only
  RR 0.2 [0.01, 4.05]
  1 study · 88 participants
  Low

Intervention not reported

The intervention showed no clear difference in proven necrotising enterocolitis number of infants with the event (low certainty).

• Intravenous in‐line filters for preventing morbidity and mortality in neonates 2015 · Cochrane Headline outcomes only
  RR 0.2 [0.01, 4.05]
  1 study · 88 participants
  Low

Intervention not reported

The intervention probably leads to lower composite thrombus, proven or unproven sepsis, necrotising… (moderate certainty).

• Intravenous in‐line filters for preventing morbidity and mortality in neonates 2015 · Cochrane Headline outcomes only
  RR 0.38 [0.19, 0.77]
  1 study · 88 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in localised phlebitis number of infants with the event (low certainty).

• Intravenous in‐line filters for preventing morbidity and mortality in neonates 2015 · Cochrane Headline outcomes only
  RR 1.22 [0.4, 3.77]
  3 studies · 641 participants
  Low

Single vs combination IV antibiotics

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 265 participants
  Low

Oral antibiotics vs IV antibiotics

The review found no eligible studies for this question.

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oral antibiotics vs IV antibiotics

The review found no eligible studies for this question.

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Single vs combination IV antibiotics

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 146 participants
  Low

Single vs combination IV antibiotics

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 34 participants
  Low

Single vs combination IV antibiotics

The review found no eligible studies for this question.

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Nebulised antibiotics vs IV antibiotics

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 54 participants
  Very low

Nebulised antibiotics vs IV antibiotics

The review found no eligible studies for this question.

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Nebulised antibiotics vs IV antibiotics

The review found no eligible studies for this question.

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found